Initial assessment for patients with HIV: Difference between revisions
From IDWiki
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
= History = |
== History == |
||
* Date and context of diagnosis |
* Date and context of diagnosis |
||
| Line 5: | Line 5: | ||
* Sexual history |
* Sexual history |
||
= Investigations = |
== Investigations == |
||
* HIV-specific |
* HIV-specific |
||
| Line 22: | Line 22: | ||
** Urinalysis (glucose and protein) |
** Urinalysis (glucose and protein) |
||
= Initial regimens = |
== Initial regimens == |
||
* All are integrase inhibitor with two nucleoside analogues |
* All are integrase inhibitor with two nucleoside analogues |
||
Revision as of 15:11, 17 August 2019
History
- Date and context of diagnosis
- History of [HIV opportunistic infections](../Complications/Opportunistic infections/Opportunistic infections.md)
- Sexual history
Investigations
- HIV-specific
- CD4 count
- HIV-RNA viral load
- HLA B5701 genotyping (for abacavir)
- Genetic resistance assays
- G6PD deficiency
- STIs and coinfections
- Hepatitis A, B, and C serologies
- Syphilis
- Three-site mucosal (genital/rectal/throat) NAAT for chlamydia and gonorrhea
- Routine
- CBC, lytes, creatinine
- Fasting lipids
- Urinalysis (glucose and protein)
Initial regimens
- All are integrase inhibitor with two nucleoside analogues
- Consider one of the [HIV single-tablet regimens](Single-tablet regimens.md)
- Triumeq (if HLA B5701 negative): dolutegravir, abacavir, and lamivudine
- Truvada (tenofovir/TDF and emtricitabine) with either dolutegravir or raltegravir
- Stribild: elvitegravir/cobicistat/tenofovir disoproxil/emtricitabine
- Complera: emtricitabine/rilpivirine/tenofovir disoproxil
